Tag: desensitisation
Transplanting the “untransplantable”: French guidelines open doors for imlifidase
A “major breakthrough in kidney transplantation”—that is how imlifidase has been described in new French consensus guidelines on the drug’s use that have been...
Imlifidase receives provisional approval in Australia for kidney transplant desensitisation
Hansa Biopharma has announced that the Australian Therapeutic Goods Administration (TGA) has provisionally approved Idefirix (imlifidase) as desensitisation treatment for highly sensitised patients prior...
New guideline supports kidney exchange programmes and “integrated approach” in sensitised...
A new guideline on the management of highly sensitised kidney transplant patients—those who have high levels of human leukocyte antigens (HLAs) and are therefore more...
Scottish Medicines Consortium recommends Idefirix for highly sensitised kidney transplant patients
Hansa Biopharma recently announced a recommendation by the Scottish Medicines Consortium (SMC) for its “first-in-class” treatment Idefirix (imlifidase) in the desensitisation of highly sensitised adult...
Hansa Biopharma enrols first patient in US pivotal trial of kidney...
Hansa Biopharma recently announced that the first patient has been enrolled in its CONFIDES trial—a US pivotal, open-label, randomised controlled study—at the Columbia University Medical Center...